Tralokinumab

Adbry targets interleukin-13 (IL-13), a cytokine that drives inflammatory processes that drive symptoms of atopic dermatitis. Credits: Evgeniia Primavera / Shutterstock. Leo Pharma has announced long term safety and efficacy data for its atopic dermatitis treatment, Adbry (tralokinumab-ldrm), demonstrating the drug’s ability to drive clear or almost clear skin for up to six years. Among patients enrolled in the Phase III ECZTEND study (NCT03587805) who have were on long-term (maintenance) treatment with Adbry, 92.9% of patients observed a reduction of at least 75% on the Eczema Area and Severity Index (EASI-75) at week 248. Additionally, 66.7% of patients achieved clear or almost clear skin, as assessed by the Investigator’s Global Assessment (IGA) scale. No new safety signals were identified. The results were presented in a poster at the Fall Clinical Dermatology Conference, which was held in Las Vegas, Nevada from 24-27 October. Adbry was approved by the US Food and Drug Administration (FDA) in 2021 for the treatment of adults with moderate-to-severe atopic dermatitis. The label was expanded in 2023 when Adbry gained an FDA approval for use in adolescents aged 12 and older, whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. An alternative mode of administration after the approved by the FDA its single dose autoinjector in June 2024. In 2023, LEO generated net sales of DKK 11.4bn ($1.7bn), growth which was driven by growth of Adbry, as per the company’s 2023 annual results. GlobalData’s consensus forecasts project that Adbry will generate global sales of $1.3bn in 2030. See Also: Pharma companies must adapt to keep pace with AI developments, say experts AF stroke patients could benefit from earlier anticoagulant administration GlobalData is the parent company of Pharmaceutical Technology . Participants enrolled in the open label ECZTEND were previously assessed in multiple monotherapy and combination therapy studies of Adbry. Among these studies are the Phase III ECZTRA 1 (NCT03131648) and ECZTRA 2 (NCT03160885) studies of monotherapy Adbry and the Phase III ECZTRA 3 study (NCT03363854) of a Adbry/topical corticosteroid combination therapy. Patients were eligible to enroll in ECZTEND after completion of their respective parent trials regardless of their treatment response or whether they received Adbry or placebo treatment. Adbry targets interleukin-13 (IL-13), a cytokine that drives inflammatory processes that drive symptoms of atopic dermatitis.

AF makes patients five times as vulnerable to strokes. Credit: meeboonstudio / Shutterstock. Patients with atrial fibrillation (AF) who have a stroke may benefit from taking anticoagulants earlier than is currently recommended. This is according to two new studies which suggest that AF patients who take blood-thinning drugs earlier are less likely to have a second stroke and show no increased risk of a brain bleed. AF means that patients suffer from an irregular heartbeat, which can sometimes result in clots in the heart, which in turn can cause strokes if they reach the brain. AF patients are five times more vulnerable to the risk of strokes for this reason. 8MM, diagnosed prevalent cases of AF, N, both sexes, ages ≥40 years, 2022 According to GlobalData, there were over 14 million total prevalent cases of AF in the eight major markets (8MM: the US, France, Germany, Italy, Spain, the UK, Japan and Canada) in 2022. In its 2023 report, it forecasted that cases would see an AGR of over 2% between 2022 and 2032. GlobalData is Pharmaceutical Technology ‘s parent company. See Also: LEO’s Adbry demonstrates long-term efficacy in atopic dermatitis GSK pumps up to $800m for US manufacturing site upgrade Of these markets, GlobalData expects Canada to have the highest AGR of 3.04%, which would put the total number of prevalent cases in the country at 712,577 by 2032. US AGR is expected to be second highest, at 2.76% (giving it 5,517,206 prevalent cases by 2023), and Spain will be third, with an AGR of 2.26% and 1,149,257 cases by 2023. The report explains: “Any change in the total prevalent cases of AF is attributable to changing population demographics in the 8MM.” Current advice recommends that AF stroke patients should have to wait up to 14 days before receiving anticoagulants (blood thinners). This is because, on rare occasions, anticoagulants can cause bleeding in the brain. UK guidelines are varied and depend on the severity of the stroke, but suggest that those who have had a moderate or severe stroke should wait at least five days before starting blood thinning treatments. However, there has been a lack of research on the impact of early compared to delayed anticoagulant treatment for AF stroke patients. This is what researchers at University College London (UCL) wanted to examine in their study, funded by the British Heart Foundation and published in the Lancet . Chief investigator David Werring said: “There are concerns that starting anticoagulants too early might increase the risk of bleeding into the area of the brain damaged by the stroke – especially in people with more severe strokes. However, starting them too late might leave the patient at risk of stroke due to further clots from the heart.” In the study, UCL researchers analysed 3,621 AF patients across 100 hospitals, all of whom had suffered a stroke between 2019 and 2024. Half of the participants began anticoagulant treatment early (meaning within four days of the stroke), and the other half had delayed treatment (between seven and 14 days). Researchers found that both groups experienced a similar number of recurrent strokes and early treatment was found to be effective. Those who received treatment early did not experience an increased risk of a bleed to the brain. Of the results, the British Heart Foundation’s chief scientific and medical officer Bryan Williams said: “This important study reveals that taking blood thinning medication within the first few days of a stroke does not come with heightened risk, as previously thought. These results could be transformative, making the case for earlier treatment that could help more people with atrial fibrillation avoid having another stroke, and the associated complications.”